SCHEDULE: Great Point Partners Discloses 5.22% Stake in Context Therapeutics

Great Point Partners, LLC and its managing members reported a 5.22% beneficial ownership stake in Context Therapeutics Inc., totaling 4,683,711 common shares.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl are the reporting persons for this Schedule 13G/A filing.
• They collectively beneficially own 4,683,711 shares of Context Therapeutics Inc. Common Stock.
• This ownership represents 5.22% of the total 89,704,194 shares of common stock outstanding, as reported by Context Therapeutics Inc. in its Form 10-Q filed on August 6, 2025.
• The shares are held through Biomedical Value Fund, L.P. (3,231,761 shares) and Biomedical Offshore Value Fund, Ltd. (1,451,950 shares), for which Great Point Partners, LLC acts as investment manager.
• The reporting persons disclaim beneficial ownership of these shares except to the extent of their respective pecuniary interests.
• All reporting persons have shared voting and shared dispositive power over the 4,683,711 beneficially owned shares.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of Context Therapeutics Inc.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant passive ownership stake by an institutional investor, which can be viewed neutrally to slightly positive as it indicates continued institutional interest in Context Therapeutics Inc.

Positives

• The disclosure of a 5.22% passive ownership stake by Great Point Partners, LLC, a specialized biomedical investment firm, can be interpreted as a vote of confidence in Context Therapeutics Inc. by an institutional investor.

Future Outlook

No forward-looking statements or guidance regarding Context Therapeutics Inc.'s operations or financial performance are provided in this beneficial ownership report.

Management Comments

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Context Therapeutics Inc.

Industry Context

This filing represents a routine disclosure of a passive investment by an institutional fund in a publicly traded company, likely within the biotechnology or pharmaceutical sector, given the names of the investment funds involved (Biomedical Value Fund, Biomedical Offshore Value Fund). It reflects ongoing institutional interest in Context Therapeutics Inc. but does not provide specific insights into broader industry trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.

Key Dates

Recommendation

This Schedule 13G/A filing is a routine disclosure of a passive ownership stake by an institutional investor and does not contain sufficient information regarding the company's financial performance, strategic direction, or market valuation to warrant a specific buy or sell recommendation. The existing stake by Great Point Partners, LLC, suggests continued institutional interest, supporting a 'hold' stance for current investors pending further operational or financial updates from Context Therapeutics Inc.

Keywords

Context Therapeutics, Great Point Partners, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology